StockData
Viridian Therapeutics, Inc.\DE logo

Viridian Therapeutics, Inc.\DE (VRDN) shareholders

VRDNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30255% above fair value
$30.12+0.06 (+0.20%)

Close on Nov 18, 2026Market cap $3.41BP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
100.0%
136M of 113M shares
Institutional holders
214
47 new, 55 sold out
Net institutional buying
24M
In Q2 2026
Insider trades, 12 months
1 buys · 3 sales
Net bought $19.58M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Fairmount Funds Management LLC
Joint filing with Fairmount Healthcare Fund II GP LLC (14.04%)
17,201,80014.04%13D (active) amendmentMay 11, 2026
Abigail P. Johnson
Joint filing with FMR LLC (14.50%)
7,625,54214.50%13G (passive)Jan 10, 2024
Bellevue Asset Management AG
Joint filing with Bellevue Group AG (6.60%)
6,726,1446.60%13G (passive)Mar 31, 2026
Paradigm BioCapital Advisors LP
Joint filing with Paradigm BioCapital Advisors GP LLC (6.10%), Senai Asefaw, M.D. (6.10%) and 1 more
6,723,7886.10%13G (passive) amendmentJun 30, 2026
T. Rowe Price Associates, Inc.5,748,4265.20%13G (passive)Jun 30, 2026
Point72 Capital Advisors, Inc.
Joint filing with Point72 Asset Management, L.P. (5.00%), Steven A. Cohen (5.00%)
5,687,5075.00%13G (passive)Aug 19, 2026
BlackRock, Inc.3,426,4506.50%13G (passive) amendmentDec 31, 2023
Kynam Capital Management, LP
Joint filing with Kynam Capital Management GP, LLC (5.76%), Yue Tang (5.76%)
05.76%13G (passive)Mar 31, 2025
Kynam Capital Management GP, LLC
Joint filing with Kynam Capital Management, LP (5.70%), Yue Tang (5.70%)
05.70%13G (passive) amendmentJun 30, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of VRDNValueChange% of portfolio
FMR LLC16,604,74014.66%$305.03M+1,225,3630.01%
BlackRock, Inc.8,551,4887.55%$157.09M+720,0130.00%
Bellevue Group AG6,731,9095.94%$123.67M+5,7652.60%
Paradigm Biocapital Advisors LP6,723,7885.93%$123.52M+3,574,8952.31%
Kynam Capital Management, LP6,453,8775.70%$118.56M+4,112,2256.55%
State Street Corp6,124,9765.41%$112.52M+1,452,0910.00%
Price T Rowe Associates Inc /Md/5,748,4105.07%$105.60M+2,542,3750.01%
Fairmount Funds Management LLC5,090,9284.49%$93.52M+1,176,4706.18%
Vanguard Capital Management LLC4,576,8604.04%$84.08M+409,6590.00%
Deep Track Capital, LP3,592,7403.17%$66.00M+2,198,7960.96%
VR Adviser, LLC3,257,9172.88%$59.85M−624,7921.81%
Wellington Management Group Llp3,128,3622.76%$57.47M+49,8080.01%
Vanguard Portfolio Management LLC2,752,8272.43%$50.57M+1,111,3500.00%
Geode Capital Management, LLC2,501,8692.21%$45.97M+168,6560.00%
Avoro Capital Advisors LLC2,500,0002.21%$45.93M+1,000,0000.41%
Baker Bros. Advisors LP2,383,0252.10%$43.78M+411,3470.22%
Point72 Asset Management, L.P.2,343,2082.07%$43.04M+2,020,3720.05%
Caligan Partners LP2,193,9811.94%$40.30MNew1.90%
Novo Holdings A/S2,135,0001.88%$39.22M+135,0002.28%
Tang Capital Management LLC1,792,6261.58%$32.93M–1.50%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026214136M100.0%47 / 9650 / 5539M16M
Q1 2026225112M99.2%49 / 8067 / 5028M17M
Q4 2025229108M95.2%77 / 8545 / 1532M18M
Q3 202516994M82.5%17 / 5365 / 185M7M
Q2 202517095M83.8%22 / 6165 / 2810M7M
Q1 202517691M80.7%26 / 6854 / 2710M9M
Q4 202417891M80.4%42 / 7942 / 2415M11M
Q3 202416588M77.3%45 / 6541 / 1629M7M
Q2 202413870M61.6%20 / 7028 / 1611M13M
Q1 202413672M64.0%23 / 6434 / 1917M5M
Q4 202313261M53.6%25 / 4943 / 1621M10M
Q3 202312350M44.3%14 / 5536 / 188M4M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

257 funds held VRDN in Q2 2026, 34% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of VRDNValue% of fundAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF3,923,6203.46%$72.08M0.67%Jun 30, 2026
Vanguard Total Stock Market Index Fund3,336,9702.95%$61.30M0.00%Jun 30, 2026
iShares Russell 2000 ETF2,348,6042.07%$43.14M0.05%Jun 30, 2026
Fidelity Advisor Biotechnology Fund1,782,4641.57%$33.72M1.53%Jul 31, 2026
Select Health Care Portfolio1,500,0001.32%$26.43M0.46%May 31, 2026
T. Rowe Price Health Sciences Fund, Inc.1,447,7421.28%$26.60M0.22%Jun 30, 2026
Strategic Advisers Fidelity U.S. Total Stock Fund1,386,3191.22%$24.43M0.01%May 31, 2026
T. Rowe Price New Horizons Fund, Inc.1,351,6961.19%$24.83M0.17%Jun 30, 2026
Select Biotechnology Portfolio1,308,3041.15%$23.05M0.44%May 31, 2026
Fidelity Small Cap Growth Fund1,268,9901.12%$24.01M0.27%Jul 31, 2026
Vanguard Extended Market Index Fund1,130,4241.00%$20.77M0.02%Jun 30, 2026
Fidelity Stock Selector Small Cap Fund1,089,1960.96%$20.61M0.28%Jul 31, 2026
Fidelity Small Cap Index Fund987,1990.87%$18.68M0.05%Jul 31, 2026
Vanguard Explorer Fund960,5000.85%$18.17M0.08%Jul 31, 2026
Fidelity Series Small Cap Opportunities Fund791,8420.70%$14.98M0.32%Jul 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Stephen F. MahoneyPresident and CEO, Director33,3490.03%Mar 9, 2026
Jennifer TousignantChief Legal Officer0–Aug 20, 2026
Radhika TripuraneniChief Medical Officer40,0000.04%Aug 18, 2026
Seth HarmonChief Financial Officer7,8500.01%Mar 9, 2026
Thomas W. BeethamChief Operating Officer13,3610.01%Mar 9, 2026
Jennifer K. MosesDirector––Jul 2, 2026
Sarah GheuensDirector––Jul 2, 2026
Jeffrey Robert AjerDirector––Jul 2, 2026
Tomas KiselakDirector––Jul 2, 2026
Arlene MorrisDirector––Jul 2, 2026
Christopher W. CainDirector––Jul 2, 2026
Funds Management LLC FairmountDirector, 10% owner3,459,9133.05%May 13, 2026
Healthcare Fund II GP LLC FairmountDirector, 10% owner3,914,4583.46%May 13, 2026
Healthcare Fund II L.P. FairmountDirector, 10% owner5,090,9284.49%May 13, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Jennifer Tousignant
Chief Legal Officer
Aug 19, 2026Sale−4,212$24.50$103.19K0
Jennifer Tousignant
Chief Legal Officer
Aug 19, 2026Option exercise+10,000$14.41$144.10K10,000
Jennifer Tousignant
Chief Legal Officer
Aug 19, 2026Sale−10,000$24.50$245.00K0
Radhika Tripuraneni
Chief Medical Officer
Aug 14, 2026Option exercise+40,000$13.21$528.40K40,000
Healthcare Fund II L.P. Fairmount
Director, 10% owner
May 11, 2026Buy+1,176,470$17.00$20.00M5,090,928
Seth Harmon
Chief Financial Officer
Mar 3, 2026Tax withholding−2,031$30.19$61.32K7,850
Thomas W. Beetham
Chief Operating Officer
Mar 3, 2026Tax withholding−3,048$30.19$92.02K13,361
Jennifer Tousignant
Chief Legal Officer
Mar 3, 2026Tax withholding−1,675$30.19$50.57K3,494
Stephen F. Mahoney
President and CEO, Director
Mar 3, 2026Tax withholding−7,408$30.19$223.65K33,349
Thomas W. Beetham
Chief Operating Officer
Mar 3, 2026Tax withholding−3,138$29.32$92.01K13,271
Thomas W. Beetham
Chief Operating Officer
Mar 3, 2026Option exercise+9,409––16,409
Stephen F. Mahoney
President and CEO
Mar 3, 2026Option exercise+18,357––40,757
Stephen F. Mahoney
President and CEO
Mar 3, 2026Tax withholding−7,627$29.32$223.62K33,130
Seth Harmon
Chief Financial Officer
Mar 3, 2026Tax withholding−2,091$29.32$61.31K7,790
Seth Harmon
Chief Financial Officer
Mar 3, 2026Option exercise+6,267––9,881
Jennifer Tousignant
Chief Legal Officer
Mar 3, 2026Tax withholding−1,724$29.32$50.55K3,445
Jennifer Tousignant
Chief Legal Officer
Mar 3, 2026Option exercise+5,169––5,169
Jennifer Tousignant
Chief Legal Officer
Dec 31, 2025Sale−2,272$31.16$70.80K0
Healthcare Fund II GP LLC Fairmount
Director, 10% owner
Oct 23, 2025Buy+454,545$22.00$10.00M3,914,458
Funds Management LLC Fairmount
Director, 10% owner
Jun 10, 2025Option exercise+12,500$12.31$153.88K3,459,913
Funds Management LLC Fairmount
Director, 10% owner
Jun 9, 2025Option exercise+1,600$7.80$12.48K3,447,413
Stephen F. Mahoney
President and CEO, Director
Sep 27, 2024Buy+21,400$23.33$499.26K21,400
Thomas W. Beetham
Chief Operating Officer
Sep 27, 2024Buy+5,000$23.41$117.05K6,000
Healthcare Fund II L.P. Fairmount
Director, 10% owner
Sep 13, 2024Buy+1,600,000$18.75$30.00M3,445,813
Healthcare Fund II L.P. Fairmount
Director, 10% owner
Mar 28, 2024Other+5,859––1,845,813
Healthcare Fund II L.P. Fairmount
Director, 10% owner
Mar 28, 2024Other−5,859––0
Healthcare Fund II L.P. Fairmount
Director, 10% owner
Jan 22, 2024Buy+476,190$21.00$10.00M1,839,954
Lara Meisner
Chief Legal Officer
Jun 16, 2023Option exercise+27$23.03$62229,998
Lara Meisner
Chief Legal Officer
Jun 16, 2023Sale(10b5-1 plan)−27$28.35$76529,971
Lara Meisner
Chief Legal Officer
Jun 15, 2023Option exercise+2,269$23.03$52.26K32,240
Lara Meisner
Chief Legal Officer
Jun 15, 2023Sale(10b5-1 plan)−2,269$28.02$63.58K29,971
Lara Meisner
Chief Legal Officer
Jun 6, 2023Option exercise+5,126$18.51$94.88K35,097
Lara Meisner
Chief Legal Officer
Jun 6, 2023Sale(10b5-1 plan)−5,126$25.02$128.25K29,971
Lara Meisner
Chief Legal Officer
Jun 5, 2023Option exercise+499$18.51$9.24K30,470
Lara Meisner
Chief Legal Officer
Jun 5, 2023Sale(10b5-1 plan)−499$25.03$12.49K29,971
Lara Meisner
Chief Legal Officer
Jun 2, 2023Sale(10b5-1 plan)−1,875$24.21$45.39K29,971
Lara Meisner
Chief Legal Officer
Jun 2, 2023Option exercise+1,875$14.00$26.25K31,846
Scott Dunseth Myers
Chief Executive Officer, Director
Apr 12, 2023Buy+4,000$25.37$101.48K259,500
Scott Dunseth Myers
Chief Executive Officer, Director
Mar 13, 2023Buy+5,500$29.15$160.33K255,500
Lara Meisner
General Counsel and Secretary
Mar 9, 2023Sale(10b5-1 plan)−29,971$29.07$871.26K0
Scott Dunseth Myers
Chief Executive Officer, Director
Feb 6, 2023Award+250,000––250,000
Jonathan Violin
Chief Executive Officer, Director
Feb 2, 2023Option exercise+50,000$0.15$7.50K530,905
Jonathan Violin
Chief Executive Officer, Director
Feb 2, 2023Sale(10b5-1 plan)−50,000$36.80$1.84M480,905
Jonathan Violin
Chief Executive Officer, Director
Feb 2, 2023Sale(10b5-1 plan)−50,000$36.80$1.84M430,905
Lara Meisner
General Counsel and Secretary
Jan 23, 2023Option exercise+1,872$14.00$26.21K6,843
Lara Meisner
General Counsel and Secretary
Jan 23, 2023Sale(10b5-1 plan)−6,843$35.66$244.02K0
Lara Meisner
General Counsel and Secretary
Jan 23, 2023Option exercise+4,971$23.03$114.48K4,971
Barrett Katz
Chief Medical Officer
Jan 17, 2023Sale(10b5-1 plan)−24,853$37.21$924.78K0
Barrett Katz
Chief Medical Officer
Jan 17, 2023Option exercise+24,853$23.03$572.36K24,853
Barrett Katz
Chief Medical Officer
Jan 13, 2023Sale(10b5-1 plan)−4,147$37.01$153.48K0
Barrett Katz
Chief Medical Officer
Jan 13, 2023Option exercise+4,147$23.03$95.51K4,147
Barrett Katz
Chief Medical Officer
Jan 10, 2023Sale(10b5-1 plan)−47,377$35.30$1.67M0
Barrett Katz
Chief Medical Officer
Jan 10, 2023Option exercise+47,377$23.03$1.09M47,377
Barrett Katz
Chief Medical Officer
Jan 9, 2023Sale(10b5-1 plan)−12,623$33.04$417.06K0
Barrett Katz
Chief Medical Officer
Jan 9, 2023Option exercise+12,623$23.03$290.71K12,623
Lara Meisner
General Counsel and Secretary
Dec 21, 2022Sale(10b5-1 plan)−16,326$29.19$476.56K0
Lara Meisner
General Counsel and Secretary
Dec 21, 2022Option exercise+16,326$23.03$375.99K16,326
Lara Meisner
General Counsel and Secretary
Dec 20, 2022Sale(10b5-1 plan)−600$28.07$16.84K0
Lara Meisner
General Counsel and Secretary
Dec 20, 2022Option exercise+600$23.03$13.82K600
Lara Meisner
General Counsel and Secretary
Dec 16, 2022Sale(10b5-1 plan)−1,297$28.44$36.89K0

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
19.23%
17M shares short
Days to cover
9.1
At 2M shares a day
Change since last report
-5.3%
From 18M shares
Short volume, 20 days
40.0%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Viridian Therapeutics, Inc.\DE's stock actually held short. Settlement fails (shares not delivered on time) peaked at 51,630 shares on Sep 22, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Jennifer Tousignant
Officer
Aug 19, 202614,212$348.19KAug 19, 2026Restricted Stock Vesting
Thomas W. Beetham
Officer
Mar 4, 20263,048$92.00KMar 4, 2026Restricted Stock Vesting
Seth Harmon
Officer
Mar 4, 20262,031$61.31KMar 4, 2026Restricted Stock Vesting
Jennifer Tousignant
Officer
Mar 4, 20261,675$50.56KMar 4, 2026Restricted Stock Vesting
Stephen F. Mahoney
Officer, Director
Mar 4, 20267,408$223.61KMar 4, 2026Restricted Stock Vesting
Jennifer Tousignant
Officer
Dec 31, 20252,272$70.80KDec 31, 2025ESPP Purchase
Meisner Lara
Former Officer
Dec 18, 20239,375$198.38KDec 18, 2023Option Granted 02/02/2022
Humer Kristian
Former CFO
Dec 12, 2023252,600$4.33MDec 12, 2023Option Granted - 07/26/2021
Humer Kristian
Former Officer
Dec 7, 202324,900$470.86KDec 7, 2023Option Granted - 07/26/2021
Meisner Lara
Former Officer
Dec 1, 20233,125$53.03KDec 1, 2023Option Granted 09/22/2021
Myers Scott Dunseth
Former Officer and Director
Nov 16, 202335,368$535.12KNov 16, 2023Restricted Stock Vesting
Meisner Lara
Officer
Jun 2, 202312,469$305.49KJun 2, 2023Stock Option Grant

See a number that looks wrong?